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It is well established that impaired GABAergic inhibition within neuronal networks can lead to hypersynchronous firing
patterns that are the typical cellular hallmark of convulsive epileptic seizures. However, recent findings have highlighted that
a pathological enhancement of GABAergic signalling within thalamocortical circuits is a necessary and suﬃcient condition for
nonconvulsive typical absence seizure genesis. In particular, increased activation of extrasynaptic GABAA receptors (eGABAAR)
and augmented “tonic” GABAA inhibition in thalamocortical neurons have been demonstrated across a range of genetic and
pharmacological models of absence epilepsy. Moreover, evidence from monogenic mouse models (stargazer/lethargic) and the
polygenic Genetic Absence Epilepsy Rats from Strasbourg (GAERS) indicate that the mechanism underlying eGABAAR gain of
function is nonneuronal in nature and results from a deficiency in astrocytic GABA uptake through the GAT-1 transporter. These
results challenge the existing theory that typical absence seizures are underpinned by a widespread loss of GABAergic function
in thalamocortical circuits and illustrate a vital role for astrocytes in the pathology of typical absence epilepsy. Moreover, they
explain why pharmacological agents that enhance GABA receptor function can initiate or exacerbate absence seizures and suggest
a potential therapeutic role for inverse agonists at eGABAARs in absence epilepsy.
1. Introduction
Typical absence epilepsy is characterised by the regular
occurrence of nonconvulsive seizures that result in periods
of sudden and brief (average ≈10 seconds, range ≈4–
40 seconds) loss of consciousness. In the electroencephalo-
gram (EEG), human absence seizures are typified by the
appearance of generalized, synchronous, and bilateral “spike
(or polyspike) and slow wave discharges” (SWD) occurring
at frequencies between 2.5–4Hz [1, 2]. Although typical
absence seizures are significant clinical features of many gen-
eralized idiopathic epilepsies (IGEs), as defined by the classi-
fication of the International League Against Epilepsy (ILAE)
[3], they are the only neurological symptom presented in
childhood absence epilepsy (CAE). CAE has an annual inci-
dence of approximately 2–8 per 100,000 children under 16
years of age, with seizure onset typically occurring between 3
and 8 years of age and seizure frequency often as high as sev-
eral hundred events per day [2]. Absence seizures associated
with CAE are not triggered by visual or other sensory stimuli
and are not usually associated with neurometabolic or neuro-
physiological deficits, a factor which is thought to contribute
to ∼70% spontaneous remission rates in adolescence [2,
4]. Nonetheless, in this pure absence epilepsy phenotype,
there is a consensus, based upon older invasive studies and
more recent imaging investigations, that seizure genesis and
propagation occur as a result of aberrant electrical activity
in reciprocally connected thalamic and cortical regions (i.e.,
thalamocortical circuits) without significant involvement of
other brain areas including hippocampus and limbic regions
which are often associated with convulsive seizures [5–9].
In fact, recent observations in humans suggest that seizure
genesis occurs due to paroxysmal activation of discrete
frontal and parietal cortical territories prior to spread into
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other cortical and thalamic regions [5–8]. This review will,
therefore, focus on the key cellular elements of thalam-
ocortical circuits and in particular upon thalamocortical
neurons.
γ-aminobutyric acid (GABA) is the principal inhibitory
neurotransmitter in the brain, and its actions are mediated
largely by a family of ubiquitously expressed ligand-gated
ion channels known as GABAA receptors [10]. GABAA
receptors are pentameric assemblies comprising several
distinct subunits which open upon GABA binding leading to
an increase in membrane permeability to both chloride and
bicarbonate ions [11]. Typically this occurs when GABA is
released from presynaptic terminals causing a transient rise
in GABA concentration within the synaptic cleft and acti-
vation of postsynaptic receptors. The resulting brief change
in membrane conductance underlies “phasic” GABAAergic
inhibition and generation of the “classical” inhibitory
postsynaptic potential (IPSP). However, it has come to
light relatively recently that GABAA receptor activation
can occur in a much more spatially and temporally diﬀuse
manner [10]. It has been demonstrated in several brain
regions including the cerebellum [12], hippocampus [13],
and thalamus [14–16] that very low (nM) concentrations
of GABA, which are found in the extracellular space, can
persistently activate a population of nonsynaptic GABAA
receptors resulting in a “tonic” increase in membrane
conductance. These peri- or extrasynaptic GABAA receptors
(eGABAARs) diﬀer from their synaptic counterparts in
having a significantly higher aﬃnity for GABA as well
as markedly slower rates of desensitization [10, 17–19]
although it has been recently demonstrated in the visual
thalamus that significant desensitization of eGABAARs can
occur at ambient GABA concentrations [20]. The divergence
in the properties of synaptic GABAARs versus eGABAARs
is conferred by receptor subunit composition, in particular,
the inclusion of the δ subunit in the case of dentate gyrus
granule cells (DGCs), cerebellar granule cells (CGCs),
thalamocortical neurons and some cortical neurons [13–
16, 21, 22], and α5 subunits in CA1 and CA3 hippocampal
pyramidal cells [23–25]. Nineteen GABAA receptor subunits
have been cloned from the mammalian CNS (α(1−6),
β(1−3), γ(1−3), δ, ε, θ, π, ρ(1−3)) oﬀering the potential for an
enormous heterogeneity in GABAA receptor assembly. In
reality however, only about twenty to thirty of the potential
combinations have been shown to exist in the brain. The
most commonly expressed subunit combination is α1, β2,
γ2 (with stoichiometry of 2α and 2β subunits and a single
γ subunit [26, 27]) whilst other common arrangements
include α2β3γ2 and α3β3γ2. Significantly, light microscopic
immunofluorescence and EM immunogold methods have
established that the postsynaptic densities of GABAergic
synapses are highly enriched with receptors including α(1−3),
α6, β(2−3), and γ2 subunits [28, 29] suggesting that these
subunits form the GABAA receptors responsible for classical
“phasic” inhibition. However, in contrast to the aforemen-
tioned subunits which are enriched in the postsynaptic
density but also abundant at extrasynaptic locations [30, 31],
some GABAA receptor subunits, especially δ, are not found
in the synapse and are exclusively peri- or extrasynaptically
located [21]. Extrasynaptic receptors containing the δ
subunit are commonly found to coassemble with α4 or α6
subunits (α4/α6βXδ) whilst α5-containing receptors are also
mostly extrasynaptic despite usually containing the typically
synaptically located γ2 subunit (α5βXγ2). A recent study
by Kasugai et al. [32] has demonstrated the presence of α1
and α2 subunits as well as β3 subunits at extrasynaptic
locations on the soma of CA1 pyramidal neurons
suggesting these subunits may also contribute to eGABAAR
signalling and perhaps confer specific pharmacological
properties.
Thalamocortical (TC) neurons of the dorsal lateral genic-
ulate nucleus (dLGN, visual thalamus) [14], the ventrobasal
nuclei (VB, somatosensory thalamus) [14–16], and the
medial geniculate body (MGB, auditory thalamus) [33] of
rodents have been demonstrated in vitro to have robust
GABAergic tonic currents. In voltage-clamped TC neurons,
application of the GABAA receptor antagonist SR-95531 not
only completely blocks the phasic inhibitory postsynaptic
currents (IPSCs) but also produces a reduction in input
conductance accompanied by a decrease in current variance
that is indicative of block of tonically active eGABAARs. In
the thalamus, it has been estimated that approximately 80–
90% of total GABAA receptor-mediated inhibition occurs
through tonic currents resulting from activation of extrasy-
naptic GABAARs [14, 16]. In fact, it has been suggested
that tonic conductance in TC neurons (when normalized
to whole cell capacitance) may be larger than in other
regions expressing eGABAARs including the cerebellum and
dentate gyrus [16]. In all of the previously described thalamic
nuclei, there is a high expression of the GABAA receptor δ-
subunit [22, 33–35], and several studies have shown, using
selective pharmacological agents [14–16], δ-subunit knock-
out (δ−/−) [36] and α4-subunit knock-out (α−/−4 ) [37] mice
that the thalamic tonic current is mediated largely by α4β2δ
subunit-containing receptors. In particular, eGABAARs in
the thalamic nuclei are highly sensitive to the potent and
selective activator of α4-δ-containing [38] receptors 4,5,6,7-
tetrahydroisoxazolo[5,4-c]-pyridin-3-ol (THIP, Gaboxadol)
[14–16, 37] as well as ethanol [39], taurine [40], and the
anaesthetic isoflurane [41], all of which act to enhance
tonic inhibition. Conversely, the α1-selective agent zolpidem
and the nonselective benzodiazepine midazolam increase the
decay time of sIPSCs in VB neurons without eﬀects on
tonic currents and the inverse agonist Ro 15-4513, a potent
activator of α4-γ2 subunit-containing receptors [38], also
had no eﬀect of tonic current in VB [15]. Functionally,
eGABAARs in the thalamus have been suggested to play
a role in switching the behavioural state-dependent TC
neuron firing modes [14] and modulating the temporal
precision of rebound low-threshold Ca2+ spikes (LTS) [34].
Furthermore, tonic inhibition in TC neurons is likely to
play a significant role in the modulation of slow wave
sleep (SWS) activity given the integral role of TC neurons
in generating low-frequency (<4Hz) oscillations in corti-
cothalamic circuits [14, 16]. However, the potential impor-
tance of eGABAARs in pathological seizure activity associ-
ated with typical absence epilepsy has only recently been
elucidated.
Advances in Pharmacological Sciences 3
2. Enhanced Tonic GABAA Inhibition
in Thalamocortical Neurons of
Genetic Absence Epilepsy Models
It has been demonstrated in vitro using several diﬀerent
genetic animal models of absence seizures that the tonic
GABAA current in TC neurons of the VB thalamus is
enhanced in animals displaying an epileptic phenotype
compared to their respective nonepileptic control animals
(Figure 1) [36]. This was first shown in the polygenic GAERS
model but has subsequently also been demonstrated for var-
ious mice models with known, but divergent, spontaneous
monogenic mutations, including stargazer and lethargic
mice. In GAERS animals, there is a clear developmental
profile for this increased GABAergic function (Figure 1(a)).
Up to postnatal day sixteen, the tonic current in VB of
GAERS is similar to that of the nonepileptic control (NEC)
strain. However, in the 24 hour period between the postnatal
day 16-17, there is a significant (almost doubling) increase
in the amplitude of the tonic current in VB TC neurons
of the epileptic animals [36] that remains elevated well
past the time of seizure onset (around the postnatal day
30 in this strain). These data suggest that, rather than
occurring as a consequence of seizure onset, the pathological
enhancement of tonic GABA inhibition during development
in GAERS may be proepileptogenic. Moreover, despite the
full developmental profile for the monogenic lethargic and
stargazer mice being unknown, it is clear in these models that
a significant enhancement of tonic current in TC neurons is
present after seizure onset, (Figure 1(b)) [36]. In contrast,
no tonic GABAA current is detected in the GABAergic
NRT neurons of GAERS or NEC animals (unpublished
observation) as is indeed the case in normal Wistar rats
[14].
The pathological augmentation of tonic GABAA currents
in TC neurons of genetic absence models is, however, not
due to increased vesicular GABA release, overexpression of δ-
subunit containing eGABAARs, or misexpression of synaptic
GABAARs but results from a dysfunction of GABA re-uptake
by the transporter GAT-1 [36]. In fact, despite being far
less abundant in the thalamus than GAT-3 [42], GAT-1
appears to play a major role in the regulation of extrasynaptic
GABA concentration and activation of eGABAARs [36]. In
acute brain slices prepared from both GAERS and stargazer
animals, block of GAT-1 using the specific antagonist
NO711 produced no eﬀect upon the magnitude of tonic
current observed in VB TC neurons, (Figures 1(c), 1(d),
and 1(e)). In marked contrast, the block of GAT-1 in
neurons of nonepileptic mice and rats facilitated a significant
enhancement of tonic current that reached levels similar
to those found in neurons from epileptic animals, (Figures
1(c), 1(d), and 1(e)). Furthermore, in nonepileptic animals,
blockade of GAT-3 using SNAP5114 resulted in an increase
in tonic current that was significantly less than that observed
in GAERS or stargazer suggesting that the ability of GAT-1 to
compensate for the loss of GAT-3 is erased in the epileptic
strains, (Figures 1(c), 1(d), and 1(e)). These findings are
made all the more significant by the fact that expression of
both GAT-1 and GAT-3 in the thalamus appears to occur
exclusively in nonneuronal cells, specifically astrocytes [42,
43]. A malfunction in GAT-1 also underlies the increased
tonic GABAA current in TC neurons of lethargic mice [36].
In contrast to GAERS and stargazermice; however, the action
of this transporter is not inhibited in lethargic mice but
appears to be reversed. These data expand upon previous
findings that demonstrated a reduction in GABA uptake by
GAT-1 [44] and increased levels of extracellular GABA [45]
in the VB thalamus of GAERS compared to NEC. Moreover,
NO711 increases tonic GABAA current by a similar amount
in dentate gyrus granule cells of GAERS and NEC [36],
indicating that GAT-1 activity is not compromised in a
brain area that does not participate in the generation of
typical absence seizures and where the distribution of this
transporter is primarily neuronal. Indeed, the basal tonic
current of dentate gyrus granule cells is not diﬀerent between
GAERS and NEC [36], and in stargazer mice, tonic current
in both DGCs and CGCs is actually reduced compared to
WT littermates [46]. Interestingly, it has been demonstrated
previously in CGCs of GABAAR α1 subunit knock-out (α
−/−
1 )
mice that tonic currents in these neurons are also enhanced
via a reduction of GAT activity that is not due to reduction in
GAT-1 or GAT-3 expression or increased expression of either
α6 or δ subunit-containing receptors [47].
In summary; therefore, genetic models of typical absence
seizures (i.e., GAERS, stargazer, and lethargic mice) show a
brain region-specific enhancement of tonic GABAA current,
which in TC neurons is due to increased extracellular GABA
level that in turn results from a malfunction in GABA uptake
by astrocytic GAT-1.
3. Pharmacological Models of Typical Absence
Epilepsy and the Role of GABAB Receptors
As well as resulting from genetic modifications, SWDs
can be generated in genetically “normal” animals through
administration of various pharmacological agents. The
best-established pharmacological model of typical absence
seizures is achieved by the systemic administration of γ-
hydroxybutyric acid (GHB) [48–50]. However, it has been
known for some time that systemic administration of
THIP, a selective agonist at δ subunit-containing extrasy-
naptic GABAARs, also elicits SWDs in normal animals,
(Figure 2(a)) [51]. In the context of the involvement of
enhanced thalamic tonic GABAA inhibition in several genetic
models of absence epilepsy, the pharmacological induction of
seizures by THIP becomes more readily explainable. This is
because, as previously disclosed, THIP can potently enhance
tonic GABAA currents of TC neurons in nonepileptic rats,
(Figure 2(b)), [36] and mice [15, 16], thus mimicking the
enhanced thalamic tonic inhibition observed in genetic mod-
els. On the other hand, the eﬀects of GHB, which does not
bind to GABAARs and is believed to elicit absence seizures
by activation of GABABRs [50], become more diﬃcult to
interpret in light of the apparent necessity for enhanced
eGABAAR signalling during SWDs. However, it has now
been demonstrated in brain slices of Wistar rats that GHB
enhances tonic GABAA currents in TC neurons, (Figure 2(c))
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Figure 1: GAT-1 transporter dysfunction produces enhanced tonic GABAA currents in VB TC neurons in animal models of absence epilepsy.
(a) The developmental profile of enhanced thalamic tonic current observed in GAERS animals compared to NEC. At P17 (prior to seizure
onset), a significant increase in current amplitude is observed in the epileptic animal that remains elevated up to seizure onset (P30). (b)
Tonic GABAA currents in VB TC neurons of monogenic stargazer (stg) and lethargic (l hour) mice are significantly greater than nonepileptic
littermates after seizure onset. (c) Block of GAT-1 using NO711 in NEC animals elevates tonic current amplitude to levels similar to those
observed in GAERS animals. No further enhancement of tonic current in GAERS is observed when GAT-1 is blocked. Block of GAT-3
produces significant increases in tonic current in both NEC and GAERS animals although the increase is smaller in NEC where GAT-1
remains functional. Simultaneous block of GAT-1 and GAT-3 results in very large tonic currents in both GAERS and NEC animals, which
are not significantly diﬀerent from each other. (d) Graph summarising the experiments depicted in (c). (e) Graph depicting the same series
of experiments performed in stargazer mice illustrating the similar eﬀects in both models. ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001. Number of
recorded neurons for each condition is indicated in bars. (a–e) reproduced from [34].
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Figure 2: GHB and THIP enhance tonic GABAA currents in VB thalamus in vitro and induce SWDs in vivo. (a) Examples of SWDs
in bilateral EEG traces recorded from Wistar rats following selective activation of eGABAARs by intrathalamic application of THIP via
microdialysis (100 μM). The top trace shows seizures occurring in the first hour after THIP administration and the bottom the second hour.
The spectrogram (corresponding to the right hemisphere of the lower traces) clearly shows an increase in oscillatory power in the 5–7Hz
range typical of SWDs in rats. The graph (right) summarises the concentration-dependent emergence of SWDs after THIP application as the
total time spent in seizure during 20 minutes bins. (b) THIP produces robust enhancement of tonic GABAA currents in VB TC-neurons in
acute brain slices in vitro. (c) GHB produces increased tonic current in VB TC neurons. (d) Graph summarising the concentration-dependent
enhancement of thalamic tonic currents by GHB and the blocking eﬀect of the GABABR antagonist CGP55845. (e) Block of GABABRs by
CGP55845 produces a reduction of tonic GABAA currents in VB TC neurons of epileptic GAERS, stargazer, and lethargic mice. ∗P < 0.05,
∗∗P < 0.01, ∗∗∗P < 0.001. Number of recorded neurons for each condition is indicated inset into bars. (a–e) reproduced from reference [34].
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[36]. The eﬀects on tonic GABAergic inhibition in vitro
are dose dependent with concentrations used reflecting
those that are required to elicit absence seizures in vivo,
(Figure 2(d)) [52]. Moreover, the eﬀects of GHB are not due
to nonspecific binding interactions since the GHB-mediated
enhancement of tonic current is negated by the GABABR
antagonist CGP55845, (Figure 2(d)). In fact, application
of CGP55845 alone significantly reduces the tonic GABAA
current amplitude in TC neurons of Wistar rats to 74% of
the control values, indicating that facilitation of extrasynap-
tic GABAARs by GABABRs contributes approximately one
quarter of the tonic GABAA current in normal rats. Impor-
tantly, CGP55845 also reduces the tonic current in GAERS,
stargazer, and lethargic mice to about 55, 65, and 57%
of control, (Figure 2(e)), respectively, [36] suggesting that
facilitation of extrasynaptic GABAAR function by GABABR
activation contributes up to half of the pathologically
enhanced tonic current in these genetic models.
This GHB-mediated enhancement of thalamic tonic
currents is fascinating in the context of another genetic
disorder related to GABAergic system function. Succinic
semialdehyde dehydrogenase (SSADH) deficiency is an auto-
somal recessively inherited disorder that results in loss of
activity in SSADH (an enzyme responsible for metabolism
of GABA), reduced GABA breakdown, and excessive accu-
mulation of both GABA and GHB in the cerebrospinal fluid
[53, 54]. Clinical symptoms are varied but include delayed
intellectual, speech and language development, ataxia and,
significantly, generalised absence seizures [55–57]. Using a
recently developed SSADH knock-out (SSADH−/−) mouse
[53, 58, 59], we have been able to demonstrate that in these
animals, which replicate the epileptic phenotype displayed
in humans with SSADH deficiency, there is a significant
enhancement of tonic GABAA currents in TC neurons com-
pared to their WT counterparts, Figures 3(a) and 3(c) [60].
Moreover, as previously described for other genetic models
of absence seizures, a large proportion of the enhanced tonic
current is sensitive to block by GABABR antagonists further
supporting the role of these metabotropic receptors in the
pathology of absence seizures, (Figures 3(b) and 3(d)) [60].
In summary; therefore, a GAT-1 malfunction in thalamic
astrocytes of mouse and rat genetic models leads to an
increase in ambient GABA in the sensory thalamus, which
in turn elicits an enhancement in tonic GABAA inhibition
through direct activation of extrasynaptic GABAARs and
indirect facilitation of extrasynaptic GABAARs via activation
of GABABRs.
4. Enhanced Tonic GABAA Inhibition of TC
Neurons Is Necessary and Sufficient for
Typical Absence Seizure Generation
As previously described, SWDs of typical absence epilepsy
appear to be initiated in deep layers (V/VI) of the cortex
where intracellular recordings show rhythmic paroxysmal
depolarisations occurring in phase with the EEG spike
[61–63]. The action potentials associated with these syn-
chronous depolarisations in turn providestrong rhythmic
input to thalamic nuclei. In NRT neurons in vivo, the strong
converging corticothalamic input that result from cortical
volleys during SWDs produces bursts of excitatory postsy-
naptic potentials (EPSPs) that trigger T-type Ca2+-channel-
mediated LTS and bursts of action potentials. In contrast,
TC neurons receive both monosynaptic excitation directly
from corticothalamic inputs and disynaptic inhibition via
the NRT. In vivo intracellular recordings made in GAERS
have shown that during ictal activity TC neurons typically
receive sequences of one EPSP plus four to six IPSPs arriving
in phase with each EEG spike and that action potential
firing is rare [62, 64]. This is likely due to the much
stronger corticothalamic excitatory inputs into NRT neurons
compared to TC neurons [65] and the robust nature of the
LTS-driven action potential bursts of NRT neurons [62, 64].
Thus, it is highly probable although it remains to be directly
demonstrated that strong GABAergic input into TC neurons
during SWDs produces activation of eGABAARs and that the
corresponding increase in tonic current contributes to the
observed downregulation of TC neuron output during ictal
activity.
To assess the impact that the enhanced tonic GABAA
current of TC neurons might have in the expression of
absence seizures, experiments in freely moving animals are
required. Under these conditions, both the behavioural and
EEG components of the seizures can be assessed, and data
are not confounded by the concomitant use of anaesthetics
and/or analgesics. Thus, unrestrained GAT-1 KOmice (GAT-
1−/−), which have not undergone any pharmacological
treatment and whose TC neurons display enhanced tonic
GABAA currents in vitro express ethosuximide-sensitive
typical absence seizures (Figures 4(a), 4(b) and 4(c)) [36].
Furthermore, the direct injection of the selective GAT-
1 blocker NO-711 into the VB by reverse microdialysis
initiates ethosuximide-sensitive typical absence seizures in
previously nonepileptic Wistar rats (Figures 4(d) and 4(e))
[36]. On the other hand, in δ−/− mice, which exhibit a nearly
ablated tonic GABAA inhibition in TC neurons (Figure 5(a)),
systemic administration of GHB fails to induce absence
seizures (Figures 5(b) and 5(c)) [36]. Intrathalamic injection
of a δ subunit-specific antisense oligodeoxynucleotide in
GAERS strongly decreases both the tonic GABAA current
and spontaneous seizures 1-2 days after injection, whereas
a missense oligodeoxynucleotide has no eﬀect (Figures 5(d),
5(e), and 5(f)) [36]. Finally, intrathalamic administration
of THIP in normal Wistar rats elicits absence seizures in
a concentration-dependent manner, which as expected are
blocked by systemic administration of ethosuximide [36].
Taken together, these data show that enhanced tonic GABAA
inhibition in TC neurons is both necessary and suﬃcient for
the generation of typical absence seizures.
5. Conclusions and Future Perspectives
Augmented tonic GABAA inhibition in TC neurons rep-
resents the first potential molecular mechanism that is
common to both well-established pharmacological and
genetic models of typical absence seizures. Despite having
a range of divergent genetic mutations, GAERS (polygenic),
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Figure 3: SSADH-deficient mice have enhanced tonic GABAA currents in VB TC neurons. (a) and (c) VB TC neurons from SSADH−/−
mice display enhanced tonic GABAA currents compared with their WT control littermates. (b) and (d) In TTX, tonic current amplitudes in
both SSADH−/− and WT mice are reduced compared to control conditions. CGP55845 reduces the amplitude of the tonic GABAA current
observed in SSADH−/− to a similar level found in WT mice. (a–d) reproduced from reference [58].
stargazer (Ca2+ channel γ2 subunit, TARP-γ2), lethargic
(Ca2+ channel β4 subunit), SSADH−/− and GAT-1−/− mice
all display SWDs characteristic of typical absence epilepsy,
whereas in δ−/− mice drugs that commonly produce SWDs
are ineﬀective. Importantly, because powerful GABAA IPSPs
can be recorded in the vast majority of TC neurons during
absence seizures in vivo [64, 66], these findings also indicate
that model systems that aim to reproduce typical absence
seizures by blocking GABAARs of TC neurons are inherently
flawed.
The discovery of a malfunction in GAT-1 as the under-
lying abnormality that produces increased tonic GABAA
inhibition in TC neurons of genetic absence models shifts
the emphasis from a neuronal to an astrocytic aetiology
for this type of nonconvulsive epilepsy. Impaired GAT-
1 activity in GAERS is not caused by decreased thalamic
or cortical expression of GAT-1 mRNA or protein levels.
Also, no genetic variants are present in GAT-1 cDNA from
GAERS, stargazer, or lethargic mice nor are the mutations
responsible for absence seizures in stargazer and lethargic
mice present in GAERS. Future studies, therefore, may
investigate whether GAT-1 is unable to reach the outer
astrocytic membrane and/or whether there are abnormalities
in its phosphorylation processes.
Experimental typical absence seizures can be elicited
or aggravated by selective GABABR agonists and can be
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Figure 4: Loss of functional GAT-1 in TC neurons leads to SWDs. (a) In adult (P68-74) GAT-1−/− mice, tonic GABAA currents in VB TC
neurons are significantly larger than in WT littermates. (b) Simultaneous bilateral EEG traces reveal that adult GAT-1−/− mice also display
SWDs (WT animals did not display SWDs—data not shown). The spectrogram at the bottom corresponds to the EEG signal from the right
(R) hemisphere. (c) Treatment of GAT-1−/− mice with the anti-absence drug ethosuximide (200mg per kg body weight i.p.) significantly
reduces the total time spent in seizures. (d) Bilateral EEG traces from a normal Wistar rat following intrathalamic administration by reverse
microdialysis of 200 μM of the selective GAT-1 blocker NO711 (spectrogram of the L trace is illustrated below). (e) Time course of the
induction of SWDs by intrathalamic administration of NO711. (a–e) reproduced from [34].
blocked by selective GABABR antagonists, applied either
systemically or intrathalamically. Because about 50% of the
tonic GABAA current observed in TC neurons of GAERS,
stargazer, and lethargic and SSADH−/− mice is abolished
by a GABAB antagonist [36, 60], the behavioural and EEG
eﬀects of selective GABAB drugs on typical absence seizures
can no longer be simply explained by the ability of these
drugs to aﬀect GABAB IPSPs and/or presynaptic GABABRs
but should also take into account the positive modulation
by GABABRs of the tonic GABAA inhibition in TC
neurons.
From a clinical perspective, it is important to stress
that all the results reviewed above provide a mechanistic
explanation for the aggravation of absence seizures that is
observed in humans and experimental animals following
either systemic or intrathalamic administration of drugs that
increase GABA levels, including tiagabine, a GABA uptake
blocker, and vigabatrin, a GABA transaminase blocker [67–
70]. Thus, the classical approach of treating seizures by
increasing inhibition through positive modulation of GABA-
ergic neurotransmission is particularly ineﬀective in absence
epilepsy. In this circumstance, a selective reduction of tonic
GABAA inhibition in thalamic neurons presents perhaps
the best possible therapeutic intervention. Intriguingly, a
recent study demonstrated that excessive tonic GABAAergic
inhibition is also a feature of cortical neurons surrounding
the infarct site (peri-infarct) after induction of stroke in
experimental models (in this model, a reduction in GAT-
3/4 expression in neurons was observed) [71]. In the motor
cortex, where the stroke was induced, eGABAARs largely
contain α5 and δ subunits. The α5 selective benzodiazepine
inverse agonist L655,708 produced a significant reduction
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Figure 5: δ subunit containing eGABAARS in thalamocortical neurons are crucial for expression of SWDs. (a) Tonic GABAA currents
are nearly completely ablated in VB TC neurons from δ−/− mice. In comparison, WT mice display robust tonic currents as revealed by
focal application of GBZ to the recording chamber. (b) Bilateral EEG traces demonstrating that GBL (the GHB prodrug) induces SWDs
in WT littermates but not in δ−/− mice. (c) Ethosuximide-sensitive SWDs that are observed in GBL-injected WT mice are significantly
reduced in δ−/− mice. Graph summarises the total time spent in seizure. (d) Intrathalamic injection of δ subunit-specific antisense
oligodeoxynucleotides (ODN) produced a significant reduction in time spent in seizure in GAERS for two days post injection. In contrast
sham injection of a missense ODN had no significant eﬀect on the occurrence of SWDs. (e) Graph summarising the eﬀect of ODN injection
into VB thalamus upon seizure number normalized to preinjection control values. (f) Graph summarising the eﬀect of anti- and missense
ODN injection into VB thalamus of GAERS animals upon tonic current amplitude measured in vitro. Acute brain slices were prepared 1 day
after intrathalamic injections were administered. (a–f) reproduced from [34].
in the tonic current amplitude in peri-infarct neurons
of slices from poststroke animals as well as improving
the performance of animals in an in vivo motor task [71]. In a
similar manner, the gain of function of eGABAARs in typical
absence seizures provides compelling preclinical data for the
development of inverse agonists selective for α4-δ subunit
containing GABAARs which may have potential therapeutic
value in this type of nonconvulsive epilepsy.
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